000 01303 a2200325 4500
005 20250517005030.0
264 0 _c20150811
008 201508s 0 0 eng d
022 _a1751-2441
024 7 _a10.1586/17512433.2015.974556
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aAwad, Mark M
245 0 0 _aDabrafenib in combination with trametinib for the treatment of metastatic melanoma.
_h[electronic resource]
260 _bExpert review of clinical pharmacology
_cJan 2015
300 _a25-33 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xtherapeutic use
650 0 4 _aClinical Trials as Topic
650 0 4 _aHumans
650 0 4 _aImidazoles
_xadministration & dosage
650 0 4 _aMelanoma
_xdrug therapy
650 0 4 _aOximes
_xadministration & dosage
650 0 4 _aProtein Kinase Inhibitors
_xadministration & dosage
650 0 4 _aPyridones
_xadministration & dosage
650 0 4 _aPyrimidinones
_xadministration & dosage
650 0 4 _aRandomized Controlled Trials as Topic
700 1 _aSullivan, Ryan J
773 0 _tExpert review of clinical pharmacology
_gvol. 8
_gno. 1
_gp. 25-33
856 4 0 _uhttps://doi.org/10.1586/17512433.2015.974556
_zAvailable from publisher's website
999 _c24427272
_d24427272